Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers.

Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C.

Neurology. 2013 Apr 9;80(15):1385-92. doi: 10.1212/WNL.0b013e31828c2fda. Epub 2013 Mar 13.

PMID:
23486875
2.

Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.

Pyykkö OT, Lumela M, Rummukainen J, Nerg O, Seppälä TT, Herukka SK, Koivisto AM, Alafuzoff I, Puli L, Savolainen S, Soininen H, Jääskeläinen JE, Hiltunen M, Zetterberg H, Leinonen V.

PLoS One. 2014 Mar 17;9(3):e91974. doi: 10.1371/journal.pone.0091974. eCollection 2014.

3.

Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus.

Jeppsson A, Höltta M, Zetterberg H, Blennow K, Wikkelsø C, Tullberg M.

Fluids Barriers CNS. 2016 Jul 29;13(1):13. doi: 10.1186/s12987-016-0037-y.

4.

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

Agren-Wilsson A, Lekman A, Sjöberg W, Rosengren L, Blennow K, Bergenheim AT, Malm J.

Acta Neurol Scand. 2007 Nov;116(5):333-9.

PMID:
17922727
5.

Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus.

Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H.

Eur J Neurol. 2013 Feb;20(2):236-42. doi: 10.1111/j.1468-1331.2012.03781.x. Epub 2012 Jun 4.

PMID:
22672777
6.

Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.

Kang K, Ko PW, Jin M, Suk K, Lee HW.

J Clin Neurosci. 2014 Aug;21(8):1398-403. doi: 10.1016/j.jocn.2013.11.039. Epub 2014 May 14.

PMID:
24836892
7.

Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau.

Ray B, Reyes PF, Lahiri DK.

J Psychiatr Res. 2011 Apr;45(4):539-47. doi: 10.1016/j.jpsychires.2010.07.011. Epub 2010 Sep 9.

8.

Cerebrospinal fluid biomarkers in cardiac arrest survivors.

Rosén C, Rosén H, Andreasson U, Bremell D, Bremler R, Hagberg L, Rosengren L, Blennow K, Zetterberg H.

Resuscitation. 2014 Feb;85(2):227-32. doi: 10.1016/j.resuscitation.2013.10.032. Epub 2013 Nov 11.

PMID:
24231570
9.

Use of cerebrospinal fluid amyloid-β and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus.

Tarnaris A, Toma AK, Chapman MD, Keir G, Kitchen ND, Watkins LD.

J Neurosurg. 2011 Jul;115(1):145-50. doi: 10.3171/2011.2.JNS101316. Epub 2011 Mar 25.

PMID:
21438653
10.

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.

Mattsson N, Bremell D, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, Hagberg L.

BMC Neurol. 2010 Jun 22;10:51. doi: 10.1186/1471-2377-10-51.

11.

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.

Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D.

Eur J Neurol. 2007 Feb;14(2):168-73.

PMID:
17250725
12.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
13.

Cerebrospinal fluid biomarkers for prognosis of long-term cognitive treatment outcomes in patients with idiopathic normal pressure hydrocephalus.

Nakajima M, Miyajima M, Ogino I, Akiba C, Sugano H, Hara T, Fusegi K, Karagiozov K, Arai H.

J Neurol Sci. 2015 Oct 15;357(1-2):88-95. doi: 10.1016/j.jns.2015.07.001. Epub 2015 Jul 2.

14.

Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.

Jingami N, Asada-Utsugi M, Uemura K, Noto R, Takahashi M, Ozaki A, Kihara T, Kageyama T, Takahashi R, Shimohama S, Kinoshita A.

J Alzheimers Dis. 2015;45(1):109-15. doi: 10.3233/JAD-142622.

PMID:
25428256
15.

Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus.

Graff-Radford NR.

Neurology. 2014 Oct 21;83(17):1573-5. doi: 10.1212/WNL.0000000000000916.

16.

Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.

Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jørgensen HL, Rosengren L, Blennow K, Zetterberg H, Winge K.

Parkinsonism Relat Disord. 2012 Jan;18(1):69-72. doi: 10.1016/j.parkreldis.2011.08.012. Epub 2011 Aug 27.

PMID:
21873100
17.

Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.

Shahim P, Rejdak R, Ksiazek P, Blennow K, Zetterberg H, Mattsson N, Rejdak K.

Eur J Neurol. 2014 Mar;21(3):486-91. doi: 10.1111/ene.12336. Epub 2013 Dec 26.

PMID:
24372994
18.

Impact of cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus on the amyloid cascade.

Moriya M, Miyajima M, Nakajima M, Ogino I, Arai H.

PLoS One. 2015 Mar 30;10(3):e0119973. doi: 10.1371/journal.pone.0119973. eCollection 2015.

19.

Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers.

Lim TS, Choi JY, Park SA, Youn YC, Lee HY, Kim BG, Joo IS, Huh K, Moon SY.

BMC Neurol. 2014 Apr 1;14:66. doi: 10.1186/1471-2377-14-66.

20.

Elevated CNS concentrations of NFL in idiopathic normal pressure hydrocephalus (INPH) and subcortical arteriosclerotic encephalopathy (SAE).

Jellinger KA, Rösler N.

Acta Neurol Scand. 2008 Jun;117(6):435. doi: 10.1111/j.1600-0404.2007.00975.x. Epub 2008 Feb 28. No abstract available.

PMID:
18307570

Supplemental Content

Support Center